Innovent and Eli Lilly deepen partnership: $350 million upfront for oncology and autoimmune programs

Innovent Biologics

Innovent and Eli Lilly expanded their collaboration, with Eli Lilly providing $350 million upfront and committing to up to $8.5 billion in additional milestone payments for development of novel cancer and autoimmune disease therapies. Innovent leads development through Phase 2 in China; Lilly gains exclusive rights outside Greater China.

• This is Innovent and Eli Lilly's seventh partnership, deepening a relationship that began with a 2012 investment.
• Deal covers novel oncology and autoimmune candidates from discovery through Phase 2 clinical trials.
• Innovent retains rights in Greater China and receives tiered royalties on sales outside the region.